Your browser is no longer supported. Please, upgrade your browser.
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-1.57 Insider Own0.40% Shs Outstand218.78M Perf Week-3.49%
Market Cap19.01B Forward P/E25.48 EPS next Y3.55 Insider Trans-5.52% Shs Float215.56M Perf Month4.97%
Income-334.50M PEG- EPS next Q0.75 Inst Own94.80% Short Float2.21% Perf Quarter0.03%
Sales2.46B P/S7.74 EPS this Y304.40% Inst Trans0.02% Short Ratio4.26 Perf Half Y-13.02%
Book/sh10.93 P/B8.29 EPS next Y663.50% ROA-10.50% Target Price105.44 Perf Year12.33%
Cash/sh8.27 P/C10.96 EPS next 5Y25.85% ROE-14.40% 52W Range62.48 - 110.36 Perf YTD4.12%
Dividend- P/FCF- EPS past 5Y55.60% ROI13.70% 52W High-17.95% Beta0.79
Dividend %- Quick Ratio3.50 Sales past 5Y33.40% Gross Margin95.70% 52W Low44.94% ATR2.67
Employees1456 Current Ratio3.60 Sales Q/Q12.50% Oper. Margin-13.60% RSI (14)56.13 Volatility2.50% 2.98%
OptionableYes Debt/Eq0.02 EPS Q/Q-111.80% Profit Margin-13.60% Rel Volume0.83 Prev Close92.04
ShortableYes LT Debt/Eq0.01 EarningsNov 05 BMO Payout- Avg Volume1.12M Price90.56
Recom2.20 SMA202.21% SMA506.05% SMA200-2.61% Volume928,849 Change-1.61%
Jan-07-21Initiated Truist Buy $120
Jan-04-21Upgrade Guggenheim Neutral → Buy
Jun-16-20Initiated The Benchmark Company Hold
May-06-20Downgrade JP Morgan Overweight → Neutral $89 → $99
Apr-29-20Downgrade Morgan Stanley Overweight → Equal-Weight $94
Apr-01-20Upgrade Morgan Stanley Equal-Weight → Overweight $83 → $90
Mar-24-20Resumed William Blair Outperform
Mar-13-20Upgrade BofA/Merrill Neutral → Buy $83
Feb-04-20Resumed BofA/Merrill Neutral $82
Jan-03-20Reiterated BMO Capital Markets Market Perform $85 → $74
Jan-03-20Downgrade Mizuho Buy → Neutral $98 → $79
Jan-02-20Downgrade Guggenheim Buy → Neutral
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
May-21-19Initiated Credit Suisse Neutral $75
May-03-19Downgrade Barclays Overweight → Equal Weight $90 → $82
Apr-11-19Initiated Stifel Hold $82
Jan-13-21 07:25AM  
Jan-11-21 10:04AM  
08:46AM  
Jan-06-21 11:14AM  
Dec-31-20 08:52AM  
Dec-30-20 02:42PM  
07:30AM  
Dec-21-20 03:43PM  
Dec-15-20 10:37AM  
Dec-14-20 03:36PM  
01:15AM  
Dec-11-20 02:01PM  
Dec-09-20 08:00AM  
Dec-07-20 10:00AM  
10:00AM  
Dec-05-20 11:32AM  
Dec-04-20 12:30PM  
Nov-25-20 08:03AM  
Nov-24-20 01:21PM  
Nov-20-20 10:03AM  
Nov-19-20 05:20PM  
Nov-12-20 10:26AM  
08:00AM  
07:44AM  
Nov-11-20 04:02PM  
03:15AM  
Nov-10-20 07:30AM  
Nov-09-20 08:00AM  
Nov-08-20 08:20AM  
Nov-05-20 08:00PM  
04:11PM  
10:12AM  
08:15AM  
07:00AM  
06:15AM  
Nov-04-20 03:55PM  
08:25AM  
Nov-03-20 07:31AM  
Nov-02-20 02:00PM  
Oct-31-20 10:45AM  
05:29AM  
Oct-30-20 09:00AM  
06:45AM  
Oct-29-20 12:35PM  
10:51AM  
08:00AM  
Oct-27-20 04:29PM  
04:25PM  
Oct-20-20 08:00AM  
Oct-08-20 11:39AM  
Oct-05-20 12:48PM  
Sep-18-20 03:48PM  
12:11PM  
07:44AM  
06:00AM  
Sep-17-20 04:31PM  
04:03PM  
Sep-16-20 01:57PM  
Sep-15-20 08:43PM  
Sep-14-20 04:38PM  
04:31PM  
03:15PM  
07:48AM  
06:30AM  
Sep-09-20 10:05AM  
Sep-04-20 06:28PM  
Sep-03-20 11:31AM  
Sep-02-20 05:04PM  
Sep-01-20 08:00AM  
Aug-18-20 04:02PM  
Aug-07-20 09:11AM  
Aug-04-20 04:11PM  
03:00PM  
10:10AM  
09:58AM  
08:45AM  
07:00AM  
Aug-03-20 09:55AM  
08:38AM  
08:21AM  
02:08AM  
Jul-31-20 07:51PM  
Jul-30-20 07:32PM  
Jul-28-20 12:33PM  
11:40AM  
Jul-27-20 01:54PM  
Jul-24-20 02:06PM  
Jul-23-20 07:15AM  
Jul-20-20 12:53PM  
Jul-16-20 08:00AM  
Jul-15-20 01:15PM  
Jul-09-20 02:00PM  
Jul-08-20 02:17PM  
Jun-29-20 07:05AM  
Jun-26-20 10:37AM  
Jun-23-20 10:24AM  
Jun-22-20 12:05PM  
12:05PM  
09:34AM  
08:36AM  
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pasquale Maria EEVP & General CounselJan 11Option Exercise65.361278,30130,073Jan 13 04:15 PM
Pasquale Maria EEVP & General CounselDec 11Option Exercise65.361288,36629,946Dec 15 04:51 PM
Pasquale Maria EEVP & General CounselNov 12Option Exercise65.361278,30128,586Nov 16 04:56 PM
BIENAIME JEAN JACQUESDirectorNov 10Sale83.0079866,2348,646Nov 12 04:41 PM
Dhanak DashyantEVP & Chief Scientific OfficerNov 06Option Exercise65.4296162,86928,971Nov 10 04:26 PM
Dhanak DashyantEVP & Chief Scientific OfficerNov 06Sale85.1796181,84828,010Nov 10 04:26 PM
Flannelly Barry PEVP & General Manager USNov 02Option Exercise48.4420,000968,80059,984Nov 04 04:15 PM
Flannelly Barry PEVP & General Manager USNov 02Sale86.6020,0001,732,00039,984Nov 04 04:15 PM
Pasquale Maria EEVP & General CounselOct 12Option Exercise65.361288,36628,459Oct 13 05:10 PM
Pasquale Maria EEVP & General CounselOct 09Option Exercise68.621,42397,64629,754Oct 13 05:10 PM
Pasquale Maria EEVP & General CounselOct 09Sale95.001,423135,18528,331Oct 13 05:10 PM
Dhanak DashyantEVP & Chief Scientific OfficerOct 06Option Exercise65.4296162,86928,971Oct 08 04:21 PM
Dhanak DashyantEVP & Chief Scientific OfficerOct 06Sale91.9796188,38328,010Oct 08 04:21 PM
Pasquale Maria EEVP & General CounselSep 11Option Exercise65.361278,30128,331Sep 14 04:19 PM
Pasquale Maria EEVP & General CounselSep 10Option Exercise65.362,193143,33430,397Sep 14 04:19 PM
Pasquale Maria EEVP & General CounselSep 10Sale90.832,193199,19028,204Sep 14 04:19 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 08Option Exercise65.4296162,86928,971Sep 10 04:21 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 08Sale88.9496185,47128,010Sep 10 04:21 PM
DIXON WENDY LDirectorAug 27Option Exercise18.9720,000379,40034,243Aug 31 04:26 PM
DIXON WENDY LDirectorAug 27Sale94.5120,0001,890,20014,243Aug 31 04:26 PM
Pasquale Maria EEVP & General CounselAug 10Option Exercise65.361288,36628,204Aug 12 04:08 PM
Dhanak DashyantEVP & Chief Scientific OfficerAug 06Option Exercise65.4296162,86928,971Aug 10 04:20 PM
Dhanak DashyantEVP & Chief Scientific OfficerAug 06Sale97.8096193,98628,010Aug 10 04:20 PM
Stein Steven HEVP & Chief Medical OfficerJul 16Sale103.8376679,53495,468Jul 17 04:20 PM
Dhanak DashyantEVP & Chief Scientific OfficerJul 13Option Exercise65.422,419158,25128,010Jul 14 04:31 PM
Pasquale Maria EEVP & General CounselJul 10Option Exercise65.361278,30128,076Jul 14 04:39 PM
Stein Steven HEVP & Chief Medical OfficerJul 08Sale108.5661066,22296,857Jul 08 05:27 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 08Sale108.5647551,56625,926Jul 08 05:31 PM
Hoppenot HerveChairman / CEOJul 07Option Exercise73.2189,7716,572,135354,907Jul 07 07:18 PM
Stein Steven HEVP & Chief Medical OfficerJul 07Option Exercise88.6810,876964,484108,245Jul 08 05:27 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 07Sale107.983,120336,89826,401Jul 08 05:31 PM
Stein Steven HEVP & Chief Medical OfficerJul 07Sale109.5614,1591,551,32697,467Jul 08 05:27 PM
Hoppenot HerveChairman / CEOJul 07Sale110.0089,7719,874,810266,501Jul 07 07:18 PM
Wenqing YaoEVP, Head of Discovery ChemJul 06Option Exercise64.5516,5531,068,496171,906Jul 07 07:30 PM
Stein Steven HEVP & Chief Medical OfficerJul 06Option Exercise75.5233,6022,537,457112,882Jul 07 07:25 PM
Dhanak DashyantEVP & Chief Scientific OfficerJul 06Option Exercise65.4296162,86926,552Jul 07 07:13 PM
Dhanak DashyantEVP & Chief Scientific OfficerJul 06Sale106.58961102,42325,591Jul 07 07:13 PM
Stein Steven HEVP & Chief Medical OfficerJul 06Sale107.2536,1243,874,171100,750Jul 07 07:25 PM
Wenqing YaoEVP, Head of Discovery ChemJul 06Sale107.3216,5531,776,468156,258Jul 07 07:30 PM
Hoppenot HerveChairman / CEOJun 26Option Exercise64.55124,1488,013,753360,104Jun 30 04:06 PM
Hoppenot HerveChairman / CEOJun 26Sale102.91124,14812,776,071240,603Jun 30 04:06 PM
Flannelly Barry PEVP & General Manager USJun 23Option Exercise73.2159943,85336,461Jun 25 05:09 PM
Trower PaulPrincipal Accounting OfficerJun 23Option Exercise64.556,943448,17128,677Jun 25 05:15 PM
Trower PaulPrincipal Accounting OfficerJun 23Sale110.006,943763,73021,734Jun 25 05:15 PM
Flannelly Barry PEVP & General Manager USJun 23Sale110.0040044,00036,061Jun 25 05:09 PM
Dickinson Jonathan ElliottEVP, General Manager, EuropeJun 22Sale105.319,000947,79021,762Jun 23 04:17 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJun 19Option Exercise72.867,866573,11732,767Jun 23 04:33 PM
Pasquale Maria EEVP & General CounselJun 19Option Exercise72.271,423102,84025,084Jun 23 04:42 PM
Flannelly Barry PEVP & General Manager USJun 19Option Exercise73.217,181525,72143,043Jun 23 04:23 PM
Pasquale Maria EEVP & General CounselJun 19Sale100.001,423142,30023,661Jun 23 04:42 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJun 19Sale105.007,866825,93024,901Jun 23 04:33 PM
Flannelly Barry PEVP & General Manager USJun 19Sale105.007,181754,00535,862Jun 23 04:23 PM
Pasquale Maria EEVP & General CounselJun 12Option Exercise65.361278,30123,661Jun 16 04:24 PM
Pasquale Maria EEVP & General CounselJun 10Option Exercise66.643,615240,91525,726Jun 12 04:11 PM
Pasquale Maria EEVP & General CounselJun 10Sale94.513,615341,64923,534Jun 12 04:11 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 08Option Exercise65.4296162,86920,948Jun 10 04:34 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 08Sale91.8796188,28719,987Jun 10 04:34 PM
BAKER BROS. ADVISORS LPDirectorMay 28Buy102.55220529,313,198May 28 08:07 PM
Pasquale Maria EEVP & General CounselMay 11Option Exercise65.361288,36623,534May 13 04:38 PM
Dhanak DashyantEVP & Chief Scientific OfficerMay 06Option Exercise65.4296162,86920,948May 08 04:53 PM
Dhanak DashyantEVP & Chief Scientific OfficerMay 06Sale96.8496193,06319,987May 08 04:53 PM
BAKER BROS. ADVISORS LPDirectorApr 28Option Exercise13.3440,000533,60029,311,915Apr 29 04:45 PM
Pasquale Maria EEVP & General CounselApr 17Option Exercise72.279,488685,69832,837Apr 20 05:08 PM
Flannelly Barry PEVP & General Manager USApr 17Option Exercise73.216,583481,94141,925Apr 21 04:28 PM
Trower PaulPrincipal Accounting OfficerApr 17Option Exercise64.551,14373,78122,467Apr 21 04:35 PM
Trower PaulPrincipal Accounting OfficerApr 17Sale100.001,143114,30021,324Apr 21 04:35 PM
Flannelly Barry PEVP & General Manager USApr 17Sale100.006,583658,30035,342Apr 21 04:28 PM
Pasquale Maria EEVP & General CounselApr 17Sale100.009,488948,80022,899Apr 20 05:08 PM
Pasquale Maria EEVP & General CounselApr 16Option Exercise68.629,488651,06732,837Apr 20 05:08 PM
Pasquale Maria EEVP & General CounselApr 16Sale95.009,488901,36022,899Apr 20 05:08 PM
Pasquale Maria EEVP & General CounselApr 14Option Exercise65.3617,8271,165,17340,726Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 14Sale90.0017,8271,604,43022,899Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 13Option Exercise65.361278,30123,864Apr 15 04:57 PM
Pasquale Maria EEVP & General CounselApr 13Sale85.6896582,68122,899Apr 15 04:57 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 06Option Exercise65.423,844251,47423,831Apr 08 04:35 PM
Pasquale Maria EEVP & General CounselApr 06Sale85.001,842156,57024,254Apr 08 04:39 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 06Sale85.003,844326,74019,987Apr 08 04:35 PM
SWAIN PAULA JEVP, Human ResourcesMar 31Option Exercise64.552,329150,33750,132Apr 02 05:32 PM
SWAIN PAULA JEVP, Human ResourcesMar 31Sale71.442,329166,38448,493Apr 02 05:32 PM
Pasquale Maria EEVP & General CounselMar 11Option Exercise65.361288,36626,096Mar 13 04:18 PM
BROOKE PAUL ADirectorFeb 21Option Exercise13.3420,000266,800221,584Feb 25 04:39 PM
SWAIN PAULA JEVP, Human ResourcesFeb 19Option Exercise64.552,500161,37550,993Feb 21 04:11 PM
SWAIN PAULA JEVP, Human ResourcesFeb 19Sale80.002,500200,00048,493Feb 21 04:11 PM
Pasquale Maria EEVP & General CounselFeb 10Option Exercise65.361278,30119,087Feb 12 05:00 PM
Wenqing YaoEVP, Head of Discovery ChemFeb 05Option Exercise18.3217,542321,369112,850Feb 07 04:48 PM
Wenqing YaoEVP, Head of Discovery ChemFeb 05Sale75.9717,5421,332,66695,308Feb 07 04:48 PM